Novartis (NVS) said Thursday the US Food and Drug Administration has approved Fabhalta to treat adults with C3 glomerulopathy, the first therapy cleared for the condition.
The oral drug is designed to reduce protein in urine and targets a part of the immune system thought to drive the disease, the company said.
Data from a phase 3 trial showed a sustained drop in protein levels over one year, with no unexpected safety issues reported.
C3G is an uncommon kidney disorder usually diagnosed in young adults and often ends in kidney failure within a decade, according to Novartis.
The company said the treatment is also being reviewed in other regions, including Europe, China, and Japan.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。